Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years E. J. Fox, D. L. Arnold,J. A. Cohen,A. J. Coles,H. -P. Hartung, E. Havrdova, K. W. Selmaj, D. H. Margolin, L. Kasten, M. A. Panzara,D. A. S. CompstonMULTIPLE SCLEROSIS JOURNAL（2015）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
